|
| 34480368 | A pilot trial of vaccination with Carcinoembryonic antigen and Her2/neu peptides in advanced colorectal cancer. | Int J Cancer | 2022 |
| 36100309 | Phase I/II clinical trial of a helper peptide vaccine plus PD-1 blockade in PD-1 antibody-naïve and PD-1 antibody-experienced patients with melanoma (MEL64). | J Immunother Cancer | 2022 |
| 33479025 | Trial to evaluate the immunogenicity and safety of a melanoma helper peptide vaccine plus incomplete Freund's adjuvant, cyclophosphamide, and polyICLC (Mel63). | J Immunother Cancer | 2021 |
| 34413169 | Phase I/II trial of a long peptide vaccine (LPV7) plus toll-like receptor (TLR) agonists with or without incomplete Freund's adjuvant (IFA) for resected high-risk melanoma. | J Immunother Cancer | 2021 |
| 34413086 | Characteristics of Immune Memory and Effector Activity to Cancer-Expressed MHC Class I Phosphopeptides Differ in Healthy Donors and Ovarian Cancer Patients. | Cancer Immunol Res | 2021 |
| 34035112 | Immunogenicity in humans of a transdermal multipeptide melanoma vaccine administered with or without a TLR7 agonist. | J Immunother Cancer | 2021 |
| 32385144 | MHC-restricted phosphopeptide antigens: preclinical validation and first-in-humans clinical trial in participants with high-risk melanoma. | J Immunother Cancer | 2020 |
| 31248461 | A multipeptide vaccine plus toll-like receptor agonists LPS or polyICLC in combination with incomplete Freund's adjuvant in melanoma patients. | J Immunother Cancer | 2019 |
| 29157306 | A pilot study of the immunogenicity of a 9-peptide breast cancer vaccine plus poly-ICLC in early stage breast cancer. | J Immunother Cancer | 2017 |
| 27522581 | Intratumoral interferon-gamma increases chemokine production but fails to increase T cell infiltration of human melanoma metastases. | Cancer Immunol Immunother | 2016 |
| 26581199 | A randomized pilot trial testing the safety and immunologic effects of a MAGE-A3 protein plus AS15 immunostimulant administered into muscle or into dermal/subcutaneous sites. | Cancer Immunol Immunother | 2016 |
| 27522582 | Topical treatment of melanoma metastases with imiquimod, plus administration of a cancer vaccine, promotes immune signatures in the metastases. | Cancer Immunol Immunother | 2016 |
| 24756419 | Immunologic hierarchy, class II MHC promiscuity, and epitope spreading of a melanoma helper peptide vaccine. | Cancer Immunol Immunother | 2014 |
| 25126421 | A melanoma helper peptide vaccine increases Th1 cytokine production by leukocytes in peripheral blood and immunized lymph nodes. | J Immunother Cancer | 2014 |
| 23197414 | Usefulness of prestudy assessment of patient willingness to undergo tissue biopsy for correlative studies in a melanoma vaccine trial. | Clin Trials | 2013 |
| 23657629 | Activation, dysfunction and retention of T cells in vaccine sites after injection of incomplete Freund's adjuvant, with or without peptide. | Cancer Immunol Immunother | 2013 |
| 23653149 | A randomized phase II trial of multiepitope vaccination with melanoma peptides for cytotoxic T cells and helper T cells for patients with metastatic melanoma (E1602). | Clin Cancer Res | 2013 |
| 23620404 | Clinical activity and safety of combination therapy with temsirolimus and bevacizumab for advanced melanoma: a phase II trial (CTEP 7190/Mel47). | Clin Cancer Res | 2013 |
| 22130163 | The vaccine-site microenvironment induced by injection of incomplete Freund's adjuvant, with or without melanoma peptides. | J Immunother | 2012 |
| 21385453 | Shipping blood to a central laboratory in multicenter clinical trials: effect of ambient temperature on specimen temperature, and effects of temperature on mononuclear cell yield, viability and immunologic function. | J Transl Med | 2011 |
| 21976537 | Molecular insights on the peripheral and intratumoral effects of systemic high-dose rIL-2 (aldesleukin) administration for the treatment of metastatic melanoma. | Clin Cancer Res | 2011 |
| 21690475 | Randomized multicenter trial of the effects of melanoma-associated helper peptides and cyclophosphamide on the immunogenicity of a multipeptide melanoma vaccine. | J Clin Oncol | 2011 |
| 20551833 | Immunogenicity for CD8+ and CD4+ T cells of 2 formulations of an incomplete freund's adjuvant for multipeptide melanoma vaccines. | J Immunother | 2010 |
| 19185050 | Multi-peptide vaccines vialed as peptide mixtures can be stable reagents for use in peptide-based immune therapies. | Vaccine | 2009 |
| 19903780 | Effect of granulocyte/macrophage colony-stimulating factor on circulating CD8+ and CD4+ T-cell responses to a multipeptide melanoma vaccine: outcome of a multicenter randomized trial. | Clin Cancer Res | 2009 |
| 18391753 | A multipeptide vaccine is safe and elicits T-cell responses in participants with advanced stage ovarian cancer. | J Immunother | 2008 |
| 18923873 | Evaluation of the sentinel immunized node for immune monitoring of cancer vaccines. | Ann Surg Oncol | 2008 |
| 18809608 | Helper T-cell responses and clinical activity of a melanoma vaccine with multiple peptides from MAGE and melanocytic differentiation antigens. | J Clin Oncol | 2008 |
| 19055839 | The use of gamma-irradiation and ultraviolet-irradiation in the preparation of human melanoma cells for use in autologous whole-cell vaccines. | BMC Cancer | 2008 |
| 17975151 | Immunologic and clinical outcomes of a randomized phase II trial of two multipeptide vaccines for melanoma in the adjuvant setting. | Clin Cancer Res | 2007 |
| 16730266 | Immunity to melanoma antigens: from self-tolerance to immunotherapy. | Adv Immunol | 2006 |
| 15728523 | MAGE-A1-, MAGE-A10-, and gp100-derived peptides are immunogenic when combined with granulocyte-macrophage colony-stimulating factor and montanide ISA-51 adjuvant and administered as part of a multipeptide vaccine for melanoma. | J Immunol | 2005 |
| 16000961 | Autoimmune toxicities associated with the administration of antitumor vaccines and low-dose interleukin-2. | J Immunother | 2005 |
| 15314546 | Assessment of the toxicities of systemic low-dose interleukin-2 administered in conjunction with a melanoma peptide vaccine. | J Immunother | 2004 |
| 15542798 | Immunologic and clinical outcomes of vaccination with a multiepitope melanoma peptide vaccine plus low-dose interleukin-2 administered either concurrently or on a delayed schedule. | J Clin Oncol | 2004 |
| 15534486 | Competition among peptides in melanoma vaccines for binding to MHC molecules. | J Immunother | 2004 |
| 14581425 | Clinical and immunologic results of a randomized phase II trial of vaccination using four melanoma peptides either administered in granulocyte-macrophage colony-stimulating factor in adjuvant or pulsed on dendritic cells. | J Clin Oncol | 2003 |
| 12186917 | Hepatitis C virus core protein leads to immune suppression and liver damage in a transgenic murine model. | J Virol | 2002 |
| 11086025 | Interaction between complement receptor gC1qR and hepatitis C virus core protein inhibits T-lymphocyte proliferation. | J Clin Invest | 2000 |
| 9712021 | Antigen processing of two H2-IEd-restricted epitopes is differentially influenced by the structural changes in a viral glycoprotein. | J Immunol | 1998 |